2,5-bis(1-piperidylmethyl)benzene-1,4-diol
|
- $114 - $769
- Product name: 2,5-bis(1-piperidylmethyl)benzene-1,4-diol
- CAS: 1753-68-0
- MF: C18H28N2O2
- MW: 304.43
- EINECS:
- MDL Number:MFCD00185950
- Synonyms:2,5-bis(1-piperidylmethyl)benzene-1,4-diol;1,4-Benzenediol, 2,5-bis(1-piperidinylmethyl)-
4 prices
Selected condition:
Brand
- aablocks
- Crysdot
Package
- 100mg
- 250mg
- 1g
- 5g
- Manufactureraablocks
- Product numberAA0020U0
- Product description2,5-Bispiperidin-1-ylmethylbenzene-1,4-diol
- Packaging100mg
- Price$114
- Updated2026-05-28
- Buy
- Manufactureraablocks
- Product numberAA0020U0
- Product description2,5-Bispiperidin-1-ylmethylbenzene-1,4-diol
- Packaging250mg
- Price$234
- Updated2026-05-28
- Buy
- Manufactureraablocks
- Product numberAA0020U0
- Product description2,5-Bispiperidin-1-ylmethylbenzene-1,4-diol
- Packaging1g
- Price$769
- Updated2026-05-28
- Buy
- ManufacturerCrysdot
- Product numberCD11231735
- Product description2,5-Bispiperidin-1-ylmethylbenzene-1,4-diol 95+%
- Packaging5g
- Price$446
- Updated2026-05-26
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| aablocks | AA0020U0 | 2,5-Bispiperidin-1-ylmethylbenzene-1,4-diol | 100mg | $114 | 2026-05-28 | Buy |
| aablocks | AA0020U0 | 2,5-Bispiperidin-1-ylmethylbenzene-1,4-diol | 250mg | $234 | 2026-05-28 | Buy |
| aablocks | AA0020U0 | 2,5-Bispiperidin-1-ylmethylbenzene-1,4-diol | 1g | $769 | 2026-05-28 | Buy |
| Crysdot | CD11231735 | 2,5-Bispiperidin-1-ylmethylbenzene-1,4-diol 95+% | 5g | $446 | 2026-05-26 | Buy |
Properties
Melting point :196-198 °C(Solv: ethanol (64-17-5))
Boiling point :463.5±40.0 °C(Predicted)
Density :1.175±0.06 g/cm3(Predicted)
pka :10.40±0.48(Predicted)
Boiling point :463.5±40.0 °C(Predicted)
Density :1.175±0.06 g/cm3(Predicted)
pka :10.40±0.48(Predicted)
Safety Information
| Symbol(GHS): |
|
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | |||||||||||||||||||||
| Hazard statements: |
|
|||||||||||||||||||||
| Precautionary statements: |
|




